HEPLISAV
Phase 3Biologic
HEPLISAV is one of 69 biologic programs targeting Hepatitis B. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1HEPLISAV
DDynavax Technologies Corporation
Phase 3
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Epoetin Beta
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis B3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HEPLISAV. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- DDynavax Technologies Corporation